Opdivo-Yervoy Combo Shows Potential as First-line Treatment for Certain Colorectal Cancers
News
A combination of Bristol-Myers Squibb‘s Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induced promising and durable response rates in metastatic colorectal cancer patients with certain genetic abnormalities who had not received prior ... Read more